Could Pre-Surgery drugs shrink thyroid tumors and improve outcomes?
NCT ID NCT07419932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether giving targeted drugs before surgery can shrink tumors in people with locally advanced thyroid cancer. About 120 participants will receive one of several drug combinations based on their tumor's genetic profile. The goal is to see if this approach makes surgery easier and improves long-term results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Multitarget Tyrosine Kinase Inhibitors (lenvatinib, anlotinib), BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor (selpercatinib, pralsetinib)
What this could lead to
If successful, this could show that giving targeted drugs before surgery helps shrink advanced thyroid tumors, potentially leading to less extensive surgery and better long-term control.
What could go wrong
This is an early observational study, not a randomized trial, so results may not prove effectiveness. Side effects from the drugs could be serious, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••